Hi Everyone - partly inspired by attending the recent EA Global London conference a couple of weeks ago, I've written a CGD Blog with some thoughts on EA's approach to prioritisation and methods in health economics (specifically Health Technology Assessment). This is a link post and as CGD staff I have to post on our platform, but since the key target audience is EAs, I'd be delighted to hear thoughts from this community. I'll be sure to monitor the comments section and perhaps the discussion will feed into future work.
The differences between EA and health econ I highlight include:
1. Approaches to generalising cost-effectiveness evidence
2. Going beyond cost-effectiveness in determining value
3. Deliberative appraisal
4. Institutionalisation of a participatory process
Please click through for the full blog.